Mark Cuban’s Bold Challenge to CVS on Drug Pricing
Ionixx Technologies
Acing software solutions in the field of Brokerage, Post-trade, OMS, Healthcare, Web3, and Fintech.
Though Billionaire Mark Cuban’s Dallas Mavericks are currently making a playoff run, but he is grabbing headlines for reasons beyond basketball.
Last week, he posed a challenging question to CVS's drug middleman in an interview with the Capital Journal, sparked by a paid column in Forbes by David Joyner, president of CVS Caremark.
Cuban's simply asked, "Why don’t you publish your prices?". CVS responded with the expected rhetoric, but in this issue we’ll explore the heated discussion this question has caused across the HealthTech industry, focusing on drug pricing transparency and access.
But first, here is a small capsule of some crucial headlines in the HealthTech world.
News Roundup:
The Conundrum of Pharmacy Benefit Managers (PBMs)
Pharmacy Benefit Managers (PBMs) play a crucial role in the healthcare system by managing prescription drug benefits on behalf of insurers, Medicare Part D drug plans, and large employers. They negotiate with drug manufacturers and pharmacies to control drug spending, decide which drugs are covered by a plan (formulary management), and handle the processing and payment of prescription drug claims.
However, the PBM industry in the United States is highly concentrated, with three major players—CVS Health, Express Scripts, and OptumRx — dominating the market with over 80% share. This concentration raises concerns about market power and the potential for practices that may not always align with the best interests of patients. They claim that their size enables them to negotiate discounts with pharmaceutical companies, thus ensuring medication affordability for patients.
These companies have faced persistent allegations of lacking transparency and profiting substantially from their middleman role in pharmaceutical transactions. Despite claims of driving competition and securing discounts, criticisms persist regarding their opaque practices and the extent to which they benefit financially from their dominant market position.
Also, their secretive pricing strategies and nearly $250 million in undisclosed fees, as revealed by a 2017 investigation by the Ohio Department of Medicaid, have raised concerns about transparency and cost reduction claims.
Emerging Paradigms: Cost-Plus Pharmacies
In stark contrast to the murky operations of PBMs, some pharmacies like Freedom Pharmacy in Pickerington, Ohio are making waves and proposing much-needed transparency in pricing. Mark Cuban’s Cost Plus Drug Company is a pioneer in this arena, openly disclosing the costs and markups of medications.
Recommended by LinkedIn
For example, in 2021, Freedom Pharmacy sold Celecoxib, a generic anti-inflammatory drug, for just $23.05—far below the $141 copayment required by traditional insurance at other pharmacies. Such disparities underscore the potential benefits of transparency and challenge the status quo upheld by traditional PBMs.
Data-Driven Insights: The True Impact of Transparency
Recent studies and reports shed light on the tangible benefits of such transparent practices. Data shows that transparent pricing can lead to an average reduction of 30% in medication costs for consumers (Health Cost Institute, 2023). Moreover, a survey by the National Health Council found that 92% of patients are more likely to choose pharmacies that provide clear pricing upfront, indicating a strong consumer preference that could reshape industry standards.
The Future of Drug Pricing: A Turning Point?
This ongoing debate is more than just corporate rivalry; it’s a critical reflection on the ethics and future of healthcare in America. With the Federal Trade Commission’s 2022 investigation into PBM practices still underway, the industry stands at a crossroads. Will traditional PBMs adapt and embrace transparency, or will they cling to outdated models that may no longer serve the public’s best interests?
Our Expert’s Take
I once shared a screenshot and said how blown away I was by the simplicity of the transparent pricing online for drugs at Mark Cuban Cost Plus Drug Company, PBC. Seriously, go to their site right now and search for a medication - I’ll wait. The simple 15% markup infographic with numbers explaining the cost is incredibly powerful.
The response from CVS Caremark is predictable, but I think change is coming. The opacity of pricing, the crazy (secret) markups, and the middlemen lining their own pockets need to be DRAGGED out kicking and screaming, or will never see the light of day.
Happy to see a guy with tons of power and money use those resources to help his fellow Americans - because he totally doesn't need to. He could just be courtside enjoying my favorite player (Luka Doncic) ball out in the playoffs and no one would fault him for it. Overall really impressed and looking forward to more change facilitated by need vs. greed.
Conclusion: A Call to Action for Clarity
The dialogue sparked by Cuban’s challenge is a clarion call for all stakeholders in the healthcare sector to advocate for and implement greater transparency. As we continue to navigate these tumultuous waters, there's a need for more research to understand how policies promoting price transparency affect medicine prices. Collaborative studies involving governments and researchers could break the current deadlock in evidence development. We require more evidence from various countries to confirm the effectiveness of different transparency measures. Although the current evidence is limited, it suggests that implementing a national policy for price transparency throughout the supply chain could help manage medicine prices.
That's a wrap on this edition.
We'd love to hear your thoughts on it. Also, if there are any specific topics you'd like us to cover, feel free to let us know! We're always open to suggestions. info@ionixxtech.com